Pharmacokinetics of rifampin in infants and children: relevance to prophylaxis against Haemophilus influenzae type b disease. 1980

G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen

Pharmacokinetic studies of rifampin were performed in 38 infants and children after administration of three different oral formulations. Mean peak serum concentrations of from 9 to 11.5 microgram/ml were observed one hour after a 10-mg/kg dose and the average half-life was 2.9 hours. Patients who received rifampin suspension in applesauce had smaller serum concentrations and area-under-the-curve values than did those who were given suspension alone. The mixture of rifampin powder and applesauce resulted in more variable serum levels. The concentrations of drug in tears from 18 subjects were similar to those in serum. All but one of 118 saliva specimens obtained from two to eight hours after the 10-mg/kg dose had antimicrobial activity. Of samples taken at two hours, 95% contained rifampin levels that exceeded the minimal bacterial concentration for 15 Haemophilus influenzae type b strains. Bactericidal activity against Haemophilus correlated with salivary rifampin concentrations and was detectable in virtually all specimens containing greater than or equal to 0.8 microgram/ml. These data provide the pharmacokinetic basis for rifampin prophylaxis of close contacts of H influenza type b disease, but are insufficient alone to recommend routine usage of rifampin for this purpose until results of additional epidemiologic studies are available.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006193 Haemophilus influenzae A species of HAEMOPHILUS found on the mucous membranes of humans and a variety of animals. The species is further divided into biotypes I through VIII. Bacterium influenzae,Coccobacillus pfeifferi,Haemophilus meningitidis,Hemophilus influenzae,Influenza-bacillus,Mycobacterium influenzae
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012293 Rifampin A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) Rifampicin,Benemycin,Rifadin,Rimactan,Rimactane,Tubocin

Related Publications

G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
November 1987, The New England journal of medicine,
G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
March 1981, JAMA,
G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
January 1985, Pediatric infectious disease,
G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
January 1988, The New England journal of medicine,
G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
June 1987, The Pediatric infectious disease journal,
G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
June 1978, Antimicrobial agents and chemotherapy,
G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
March 1990, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
April 1988, The Pediatric infectious disease journal,
G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
November 1991, The Nurse practitioner,
G H McCracken, and C M Ginsburg, and T C Zweighaft, and J Clahsen
April 1986, American journal of diseases of children (1960),
Copied contents to your clipboard!